drugset / Trial / NCT05016245
MANDARIN (S6371)
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of TheraSphereTM yttrium \[90Y\] glass microsphere in the Chinese patients with inoperable hepatocellular carcinoma.
Timeline
- Start
- 2021-09-13
- Primary completion
- 2026-02-13
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Yttrium-90 Glass Microspheres | Unknown | 3000 mbq | — |
| Subject | Yttrium-90 Glass Microspheres | Unknown | 5000 mbq | — |
| Subject | Yttrium-90 Glass Microspheres | Unknown | 7000 mbq | — |
| Subject | Yttrium-90 Glass Microspheres | Unknown | 10000 mbq | — |
| Subject | Yttrium-90 Glass Microspheres | Unknown | 15000 mbq | — |
| Subject | Yttrium-90 Glass Microspheres | Unknown | 20000 mbq | — |